OA02.2. Survival Comparison in Patients With Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Clicks: 1
ID: 325688
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #78 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background In the treatment of esophageal squamous cell carcinoma (ESCC), previous studies have shown comparable overall survival (OS) between neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT). While NACRT typically yields a higher pathological complete response (pCR) rate, the reliability of pCR as a surrogate marker for survival remains a subject of debate. Furthermore, it is not clear if survival outcomes differ between these two preoperative approaches specifically among patients who reach pCR. Methods This study performed an integrated individual patient data (IPD) analysis using data from phase III clinical trials focused on resectable ESCC. The primary objective was to compare the prognostic outcomes of NAC versus NACRT, with a particular emphasis on the subgroup of patients who achieved pCR. Results Data from 1,044 patients (83.5% male; mean age 62.3 years) were pooled from seven randomized controlled trials across six countries. Of these, 605 patients underwent NAC and 439 received NACRT. The pCR rates were 6.9% and 34.2%, respectively. Notably, among the 192 patients who achieved pCR, the NAC group demonstrated a 5-year OS of 97.5%, compared to 70.4% in the NACRT group. Similarly, 5-year recurrence-free survival was higher for NAC (80.8%) than for NACRT (63.7%). Multivariable models confirmed that NAC was associated with a significant survival benefit in the pCR population. Conclusion Postoperative prognosis differs significantly by the type of neoadjuvant therapy, even when pCR is achieved. The exceptionally high survival rates seen in patients reaching pCR after NAC suggest that this specific group may be the most suitable candidates for exploring "watch-and-wait" strategies or the omission of surgery in future clinical trials.
Reference Key
openalex_W7203872597 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Satoru Matsuda, Jun Okui, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan, Shaoyuan Zhang, Thomas Aparic, Guillaume Piessen, Charlène van der Zijden, Bianca Mostert, Bas Wijnhoven, Takahiro Tsushima, Hiroya Takeuchi, Ken Kato, Yuko Kitagawa
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.014
URL
https://doi.org/10.1093/dote/doag077.014
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.